Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious ...
In a report released today, Brian Abrahams from RBC Capital maintained a Hold rating on Vertex Pharmaceuticals (VRTX – Research Report), ...
The "Gene Editing Therapeutics Market" report has been added tAndMarkets.com's offering.The gene editing therapeutics market is estimated to be $11 million in 2024 and is forecasted to grow at a CAGR ...